Glycine(B) antagonists and partial agonists in rodent models of Parkinson's disease - Comparison with uncompetitive N-methyl-D-aspartate receptor antagonist

Neuropharmacology

Volumn 38, Issue 1, 1999, Pages 109-119

  Karcz Kubicha, M ^a   Lorenz, B ^a   Danysz, W ^a  

^a Merz+Co Eckenheimer L ^*  (Germany)

Author keywords

Catalepsy; Glycine site antagonists; Glycine site partial agonists; Locomotion; Parkinson's disease; Rotation; Uncompetitive N methyl D aspartate receptor antagonist

Indexed keywords

GLYCINE RECEPTOR AGONIST; GLYCINE RECEPTOR ANTAGONIST; HALOPERIDOL; MRZ 2570; MRZ 2571; MRZ 2576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR AFFECTING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; CYCLOPENTANE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; BINDING COMPETITION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BINDING, COMPETITIVE; CATALEPSY; CYCLOPENTANES; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE AGENTS; HALOPERIDOL; HYPNOTICS AND SEDATIVES; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RESERPINE;

EID: 0032587705     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00165-8     Document Type: Article

References (60)

1. Berger P., Farrel D., Sharp F., Skolnick P. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex. Neurosci. Lett. 168:1994;147-150.
2. Bristow L.J., Flatman K.L., Hutson P.H. et al. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. J. Pharmacol. Exp. Ther. 277:1996;578-585.
3. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
4. Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
5. Carroll C.B., Holloway V., Brotchie J.M., Mitchell I.J. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology. 119:1995;55-65.
6. Chiamulera C., Costa S., Reggiani A. Effect of NMDA-insensitive and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology. 102:1990;551-553.
7. Coleman R.J. Current drug therapy for Parkinson's disease. A review. Drug Aging. 2:1992;112-124.
8. Danysz W., Essmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48:1994;111-118.
9. Danysz W., Gossel M., Zajaczkowski W., Dill D., Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm.-Parkinsons. 7:1994;155-166.
10. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders - a revived target for drug development. Drug News Perspect. 8:1995;261-277.
11. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
12. Elliott P.J., Close S.P., Walsh D.M., Hayes A.G., Marriott A.S. Neuroleptic induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J. Neural Transm. Parkinsons. 2:1990;91-100.
13. Feiling C. The effect of adding amantadine to optimum L-DOPA dosage in Parkinson's syndrome. Acta Neurol. Scand. 49:1973;245-251.
14. Fornstedt B. Role of catechol autoxidation in the degeneration of dopamine neurons. Acta Neurol. Scand. 129:1990;12-14.
15. Gossel M., Schmidt W.J., Löscher W., Zajaczkowski W., Danysz W. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm. Parkinsons. 10:1995;27-39.
16. Greennamyre J.T., O'Brien C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48:1991;977-981.
17. Hargreaves R.J., Rigby M., Smith D., Hill R.G. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110:1993;36-42.
18. Hauber W. Impairments of movement initiation and execution induced by a blockade of dopamine D-1 or D-2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors. Neuroscience. 73:1996;121-130.
19. Karcz-Kubicha M., Jessa M., Nazar M. et al. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology. 36:1997;1355-1367.
20. Kaur S., Starr M.S. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280:1995;159-166.
21. Klockgether T., Turski L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci. 12:1989;285-286.
22. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian action of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
23. Koek W., Colpaert F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists-relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252:1990;349-357.
24. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. Suppl. 43:1994;91-104.
25. Kretschmer B.D., Zadow B., Volz T.L., Schmidt W.J. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transm. 87:1992;23-35.
26. Kretschmer B.D., Winterscheid B., Danysz W., Schmidt W.J. Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J. Neural Transm. 95:1994;123-136.
27. Kretschmer B.D., Kratzer U., Breithecker K., Koch M. ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur. J. Pharmacol. 331:1997;109-116.
28. Krueger J.M., O'Connor A.J., Kelso S.R. Glycine site agonists exhibit subunit specific effects on NMDA receptors expressed in Xenopus oocytes. Soc. Neurosci. Abst. 23:1997;945.
29. Langston J.W., Finnegan K.T. The neurotoxicity of MPTP and its relationship to parkinsonism. ISI Atlas Sci. Pharmacol. 1:1987;147-150.
30. Lanthorn T.H. D-cycloserine: agonist turned antagonist. Amino Acids. 6:1994;247-260.
31. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
32. McAllister K.H. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 314:1996;307-311.
33. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci. Biobehav. Rev. 21:1997;469-475.
34. Mitchell I.J., Hughes N., Carroll C.B., Brotchie J.M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol. 6:1995;492-507.
35. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A pilot study of N-Methyl-D-Aspartate (NMDA) antagonist in Parkinson's disease [6]. J. Neurol. Neurosurg. Psychiatry. 55:1992;630-631.
36. Montastruc J.L., Fabre N., Rascol O., Senard J.M., Blin O. N-methyl-D-aspartate (NMDA) antagonist and Parkinsons disease - a pilot study with dextromethorphan. Mov. Disord. 9:1994;242.
37. Moore N.A., Blackman A., Awere S., Leander J.D. NMDA receptor antagonists inhibit catalepsy induced by either dopamine-D1 or dopamine-D2 receptor antagonists. Eur. J. Pharmacol. 237:1993;1-7.
38. Morelli M. Dopamine/glutamate interaction as studied by combining turning behaviour and c-fos expression. Neurosci. Biobehav. Rev. 21:1997;505-509.
39. Morelli M., Febu S., Dichiara G. Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors. Neurochem. Int. 20:1992;261S-264.
40. Murata S., Kawasaki K. Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex. Eur. J. Pharmacol. 239:1993;9-15.
41. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur. Neurol. 34:1994;20-28.
42. Ossowska K. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural Transm.-Parkinsons. 8:1994;39-71.
43. Ossowska K., Lorenc-Koci E., Wolfarth S. Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J. Neural Transm.-Parkinsons. 7:1994;143-152.
44. Papa S.M., Chase T.N. Levodopa-reduced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
45. Parsons C.G., Danysz W., Quack G. et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283:1997;1264-1275.
46. Paxinos, G., Watson, C., 1986. The rat brain in stereotaxic coordinates. Academic Press, Sydney.
47. Priestley T., Laughton P., Myers J., Lebourdelles B., Kerby J., Whiting P.J. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2a and NR1a/NR2b subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol. Pharmacol. 48:1995;841-848.
48. Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine and NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm.-Parkinsons. 4:1992;277-282.
49. Schmidt W.J., Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21:1997;381-392.
50. Schmidt W.J., Zadow B., Kretschmer B.D., Hauber W. Anticataleptic potencies of glutamate-antagonists. Amino Acids. 1:1991;225-237.
51. Schwab R.S., England A.C., Poskranzer D.C., Young R.R. Amantadine in the treatment of Parkinson's disease. J. Am. Med. Assoc. 208:1969;1168-1170.
52. Skuza G., Rogoz Z., Quack G., Danysz W. Memantine, amantadine, and l-deprenyl potentiate the action of l-DOPA in monoamine-depleted rats. J. Neural. Transm.-Gen. Sect. 98:1994;57-67.
53. Stauch Slusher B., Rissolo K.C., Jackson P.F., Pullan L.M. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J. Neural. Transm.-Gen. Sect. 97:1994;175-185.
54. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13:1990;259-265.
55. Snell L.D., Johnson K.M. Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior. J. Pharmacol. Exp. Ther. 235:1985;50-57.
56. Starr M.S., Starr B.S. Facilitation of dopamine-D1 receptor-dependent but not dopamine d(1)/d(2) receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur. J. Pharmacol. 250:1993;239-246.
57. Starr M.S., Starr B.S., Kaur S. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosici. Biobehav. Rev. 21:1997;437-446.
58. Turski L., Diedrichs S., Klockgether T. et al. Paradoxical anticonvulsant activity of the gamma-aminobutyrate antagonist bicuculline methiodide in the rats striatum. Synapse. 7:1991;14-20.
59. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-92.
60. Zigmond M.J., Hastings T.G., Abercrombie E.D. Neurochemical responses to 6-hydroxydopamine and L-DOPA therapy: implication for Parkinson's disease. Ann. Neurol. 32:1992;105-110.